Download App

Log in to access Online Inquiry
Company Overview More
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
CEO: Simpson, Adam K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > ICVX Icosavax > Detailed Quotes

ICVX Icosavax

7.800-0.410-4.99%
Close 05/19 20:00 ET
High
8.420
Open
8.070
Turnover
864.67K
Low
7.720
Pre Close
8.210
Volume
109.57K
Market Cap
309.87M
P/E(TTM)
Loss
52wk High
49.990
Shares
39.73M
P/E(Static)
Loss
52wk Low
4.000
Float Cap
146.97M
Bid/Ask %
-100.00%
Historical High
49.990
Shs Float
18.84M
Volume Ratio
0.96
Historical Low
4.000
Dividend TTM
--
Div Yield TTM
--
P/B
1.19
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.58%
Amplitude
8.53%
Avg Price
7.891
Lot Size
1
Float Cap
146.97M
Bid/Ask %
-100.00%
Historical High
49.990
Shs Float
18.84M
Volume Ratio
0.96
Historical Low
4.000
Dividend TTM
--
P/B
1.19
Dividend LFY
--
Turnover Ratio
0.58%
Amplitude
8.53%
Avg Price
7.891
Lot Size
1
Price Forecast

No Data

News

Comment